Letters to the Editor
5 November 2024
Vol. 2 No. 3 (2024)
Mavacamten’s therapeutic impact: cardiac-specific myosin inhibition in obstructive hypertrophic cardiomyopathy
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
2220
Views
542
Downloads
0
HTML
Authors
Dear Editor,
Obstructive hypertrophic cardiomyopathy (oHCM) is a hereditary cardiac condition, affecting 1 in about 500 individuals, characterized by an atypical thickening of the heart muscle, specifically the interventricular septum...
Altmetrics
Downloads
Download data is not yet available.
Citations
Geske JB, Ommen SR, Gersh BJ. Hypertrophic cardiomyopathy: clinical update. JACC Heart Fail 2018;6:364-375. DOI: https://doi.org/10.1016/j.jchf.2018.02.010
Braunwald E, Saberi S, Abraham TP, Elliott PM, Olivotto I. Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. Eur Heart J 2023;44:4622-33. DOI: https://doi.org/10.1093/eurheartj/ehad637
Zampieri M, Argirò A, Marchi A, et al. Mavacamten, a novel therapeutic strategy for obstructive hypertrophic cardiomyopathy. Curr Cardiol Rep 2021;23:79. DOI: https://doi.org/10.1007/s11886-021-01508-0
Makhija M, Bansal A, Jakhar P, Sharma L, Kumar S, Gupta D. Mavacamten: a novel avenue towards hypertrophic obstructive cardiomyopathy. Int J Basic Clin Pharmacol 2024;13:568-72. DOI: https://doi.org/10.18203/2319-2003.ijbcp20241661
Yacoub MS, El-Nakhal T, Hasabo EA, et al. A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy. Heart Fail Rev 2024;29:479-96. DOI: https://doi.org/10.1007/s10741-023-10375-6
Hegde SM, Lester SJ, Solomon SD, et al. Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2021;78:2518-32. DOI: https://doi.org/10.1016/j.jacc.2021.09.1381
How to Cite
1.
Shabbir A, Yumn L, Khan E. Mavacamten’s therapeutic impact: cardiac-specific myosin inhibition in obstructive hypertrophic cardiomyopathy. Global Cardiol [Internet]. 2024 Nov. 5 [cited 2025 Aug. 13];2(3). Available from: https://www.globalcardiology.info/site/article/view/48
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Sven Christopher Aland, Christoph Gertler, Hannah Leonie Bräunig, Timo Schröder, Frank Edelmann, Rolf Wachter, Christoph Herrmann-Lingen, Gerd Hasenfuß, Anja Sandek, Exercise capacity, iron deficiency and depressive symptoms in patients with asymptomatic chronic systolic heart failure , Global Cardiology: Vol. 2 No. 2 (2024)
- Kamilu M. Karaye, Abdulrazaq G. Habib, Karen Sliwa, Epidemiology of peripartum cardiomyopathy in Africa , Global Cardiology: Vol. 2 No. 2 (2024)
- Babalawan Muhammad, Naser A. Ishaq, Kamilu M. Karaye, Clinical profiles and short-term outcomes of women with peripartum and dilated cardiomyopathies , Global Cardiology: Vol. 2 No. 3 (2024)
- Kamilu M. Karaye, Idris Y. Mohammed, Okechukwu S. Ogah, Basil N. Okeahialam, Rationale and design for the peripartum cardiomyopathy in Nigeria (PEACE) registry , Global Cardiology: Vol. 1 No. 1 (2023)
- Kamilu M. Karaye, Idris Y. Mohammed, Hadiza Sa’idu, Naser A. Ishaq, Suleiman A. Balarabe, Jamilu Tukur, Tewogbade A. Adedeji, Olufemiwa N. Makinde, Rasaaq A. Adebayo, Prevalence of left ventricular dysfunction and relationship with serum selenium in apparently healthy pregnant women: results from the PEACE registry , Global Cardiology: Vol. 2 No. 2 (2024)
- Stefan Peters, Encasement of the left anterior descending coronary artery: association with Takotsubo syndrome, and diagnostic and therapeutic options , Global Cardiology: Vol. 1 No. 1 (2023)
- Konstantinos Stamos, Theodora Delaporta, Antonios Delaportas, Bridging the gap: integrating stress echocardiography, iFR, CFR, and FFR in the evaluation of coronary artery disease , Global Cardiology: Vol. 3 No. 1 (2025)
- Reinaldo B. Bestetti, Rosemary Furlan-Daniel, Luciano P. Pereira, COVID-19 myocarditis , Global Cardiology: Vol. 2 No. 1 (2024)
- Muhammad Shariq Usman, Arsalan Hamid, Shurjeel Uddin Qazi, Mikhail N. Kosiborod, Deepak L. Bhatt, Muhammad Shahzeb Khan, Muthiah Vaduganathan, Javed Butler, The effect of SGLT2 inhibitors on health status in patients with heart failure: a systematic review and meta-analysis , Global Cardiology: Vol. 2 No. 2 (2024)
- Muhammad Shahzeb Khan, Javed Butler, Laibah Arshad Khan, Markus S. Anker, Advanced cancer as a heart failure like syndrome due to cardiac wasting cardiomyopathy: facts and numbers , Global Cardiology: Vol. 2 No. 4 (2024)
You may also start an advanced similarity search for this article.
